Jordi Remon, Thoracic Oncologist at CIOCC Barcelona, shared a post on X:
“Krescendo 170 trial Supports in 1st L in KRASG12Cmut NSCLC we can avoid platinum-CT as divarasib + pembro reported impressive outcomes in PDL1+ and PDL1– with mPFS in PDL1 + of 19.3 mo. Benefit mainly in high PDL1.
Need data from KRESCENDO2 to confirm this important data.”
Other articles featuring Jordi Remon on OncoDaily.
